Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772525 · ClinicalTrials.gov registry record · Phase 2
Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00772525 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 31 participants.
The verdict
NCT00772525, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary objective of the study was to evaluate the effect of Nerispirdine (50 mg or 400 mg) and placebo given orally as a single dose once a week in crossover design on latency of Visual Evoked Potentials (VEP) P100 in optic nerves. Secondary objectives included evaluation of the effect of Nerispirdine on VEP amplitude and other visual parameters including visual acuity and contrast, as well as evaluation of the safety and tolerability of Nerispirdine in patients with Multiple Sclerosis (MS). Contrast sensitivity and visual acuity examinations (in addition to Optical Coherence Tomography \[OCT\] and VEPs) were needed during the screening period for defining etiologic relationships (if non-MS related impairment) and for assessing the effect of treatment of age-related eye disease versus the MS-related vision impairment.
Interventions
- DRUG Placebo
- DRUG Nerispirdine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772525
The ClinicalTrials.gov registry entry for NCT00772525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00772525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772525 about?
NCT00772525 is a clinical study titled "Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis". The primary objective of the study was to evaluate the effect of Nerispirdine (50 mg or 400 mg) and placebo given orally as a single dose once a week in crossover design on latency of Visual Evoked Potentials (VEP) P100 in optic nerves. Secondary objectives included evaluation of the effect of Neri...
What is the current status of trial NCT00772525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2008-09. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00772525?
The interventions under investigation include: Placebo (DRUG), Nerispirdine (DRUG).
Who is sponsoring clinical trial NCT00772525?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.